The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...
Confusion between approved injectable epinephrine products and unapproved nasal solutions has prompted a warning to ...
A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...
KMOV St. Louis on MSN18h
Nasal COVID vaccine developed at WashU approved for clinical trialsThe Food and Drug Administration (FDA) recently gave approval for clinical trials in the U.S. of a COVID-19 nasal vaccine ...
Inquirer on MSN3d
World’s first anti-depression nasal spray receives FDA approvalThe US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more potent ...
A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback